Atacand Use With ACE Inhibitors Recommended For Heart Failure Treatment
This article was originally published in The Pink Sheet Daily
Combination use of AstraZeneca's candesartan and ACE inhibitors is recommended for heart failure treatment by FDA's Cardiovascular & Renal Drugs Advisory Committee. CHARM-Added study shows reduction in cardiovascular mortality and hospitalization in heart failure patients using the combination therapy.
You may also be interested in...
The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products